ABSTRACT Immune checkpoint inhibitors (ICIs) are an important treatment option for patients with advanced non‐small cell lung cancer (NSCLC). There remains significant uncertainty regarding immunotherapy regimen selection and safety management for elderly lung cancer patients, due to the insufficient inclusion of geriatric patients in current clinical studies and the absence of specific management guidelines or consensus statements for immunotherapy in the elderly population. The consensus integrates the latest evidence‐based medical evidence worldwide with clinical practice experience in China. It provides recommendations on key challenges in immunotherapy for elderly patients with advanced NSCLC, including geriatric assessment, treatment regimen selection, management of adverse reactions, and future research directions, aiming to provide a reference for clinical practice.
Lin et al. (Wed,) studied this question.